S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7). (23rd June 2022) - Sureda, A.; Westin, J.; Locke, F. L.; Dickinson, M.; Ghobadi, A.; Elsawy, M.; van Meerten, T.; Miklos, D. B.; Ulrickson, M.; Perales, M.-A.; Farooq, U.; Wannesson, L.; et al.